Study guide
5.1 Acute Kidney Injury & KDIGO Staging
Professional and Linguistic Assessments Board Part 1 PLAB 1
Track your progress as you read
Finished sections get a check mark.
1 Introduction
About the PLAB 1 Exam
2 Chapter 1: Acute Medicine, Resuscitation & Clinical Emergencies
1.1 The ABCDE Approach, Adult Resuscitation & Shock 1.2 Sepsis, Sepsis Six Protocol & Septic Shock 1.3 Anaphylaxis & Acute Airway Emergencies 1.4 Clinical Toxicology & Acute Poisoning 1.5 Major Trauma, Head Injury, Burns & Environmental Emergencies
3 Chapter 2: Cardiovascular Medicine & Vascular Disorders
2.1 Acute Coronary Syndromes (STEMI & NSTEMI/Unstable Angina) 2.2 Heart Failure & Cardiogenic Shock 2.3 Cardiac Arrhythmias & Syncope 2.4 Hypertension, Valvular Heart Disease & Aortic Emergencies 2.5 Infective Endocarditis, Pericardial Disease, Myocarditis & Cardiomyopathies 2.6 Peripheral Arterial Disease, Aortic Aneurysm & Venous Disease
4 Chapter 3: Respiratory Medicine
3.1 Asthma: Diagnostic Criteria, Chronic Stepping & Acute Exacerbations 3.2 COPD: Staging, Long-Term Management & Acute Exacerbations 3.3 Pneumonia & Lower Respiratory Tract Infections 3.4 Venous Thromboembolism, Pleural Disease & Pneumothorax 3.5 Lung Cancer, Interstitial & Suppurative Lung Disease, Sleep Apnoea & Respiratory Failure
5 Chapter 4: Gastroenterology, Hepatobiliary & General Surgery
4.1 Upper Gastrointestinal Bleeding & Dyspepsia 4.2 Lower Gastrointestinal Bleeding, IBD & Colorectal Malignancy 4.3 Acute Abdomen, Bowel Obstruction & Perforation 4.4 Hepatobiliary Disease, Cirrhosis & Acute Pancreatitis 4.5 Functional, Malabsorptive & Infective Bowel Disorders, Anorectal Disease, Hernias & MASLD
6 Chapter 5: Renal Medicine, Urology & Fluid/Electrolyte Balance
5.1 Acute Kidney Injury & KDIGO Staging 5.2 Chronic Kidney Disease & Glomerular Disorders 5.3 Electrolyte Emergencies: Potassium, Sodium & Calcium 5.4 Urology: Urinary Tract Infections, Renal Colic & Urinary Retention 5.5 Urological Cancers, Prostate Disease & Scrotal Emergencies
7 Chapter 6: Endocrinology & Metabolic Medicine
6.1 Diabetes Mellitus: Diagnostic Criteria & Chronic Management 6.2 Diabetic Emergencies: DKA & Hyperosmolar Hyperglycaemic State 6.3 Thyroid Disorders: Hypothyroidism, Thyrotoxicosis & Thyroid Storm 6.4 Adrenal & Pituitary Disorders: Addisonian Crisis & Pituitary Disease
8 Chapter 7: Neurology & Neurosciences
7.1 Acute Stroke, TIA & Intracranial Haemorrhage 7.2 Acute & Chronic Headaches, Giant Cell Arteritis & CNS Infections 7.3 Seizures, Status Epilepticus & Epilepsy Management 7.4 Neuromuscular Disorders & Movement Disorders 7.5 Raised Intracranial Pressure, Brain Tumours, Cranial Nerve Lesions & Spinal Cord Disorders
9 Chapter 8: Psychiatry & Mental Health
8.1 Affective Disorders: Depression, Bipolar Disorder & Suicide Risk Assessment 8.2 Psychosis, Schizophrenia & Acute Agitation 8.3 Cognitive Disorders, Substance Misuse & the Mental Health Act 8.4 Anxiety Disorders, OCD, PTSD, Eating Disorders, Personality Disorders & Somatic Presentations 8.5 Perinatal, Child & Adolescent and Neurodevelopmental Mental Health
10 Chapter 9: Obstetrics, Gynaecology & Sexual Health
9.1 Early Pregnancy: Miscarriage & Ectopic Pregnancy 9.2 Antenatal & Peripartum Emergencies: Pre-Eclampsia & Haemorrhage 9.3 Common Gynaecological Presentations & Gynaecological Oncology 9.4 Contraception, Emergency Contraception & Sexually Transmitted Infections 9.5 Routine Antenatal Care, Labour & Obstetric Emergencies 9.6 Menopause & HRT, Subfertility, Prolapse & Urinary Incontinence
11 Chapter 10: Paediatrics & Child Health
10.1 The Febrile Child, Sepsis & Meningococcal Disease 10.2 Paediatric Respiratory Distress: Croup, Bronchiolitis & Wheeze 10.3 Paediatric Abdominal Emergencies, Dehydration & Neonatal Jaundice 10.4 Child Safeguarding, Non-Accidental Injury & Developmental Milestones 10.5 Neonatology & Congenital Heart Disease 10.6 Paediatric Orthopaedics, Growth, Childhood Cancer & Common Chronic Problems
12 Chapter 11: Musculoskeletal Medicine & Rheumatology
11.1 Inflammatory Arthropathies & Connective Tissue Diseases 11.2 Crystal Arthropathies (Gout & Pseudogout) & Septic Arthritis 11.3 Osteoporosis, Common Fractures & Orthopaedic Emergencies 11.4 Osteoarthritis, Low Back Pain, Polymyalgia Rheumatica, Fibromyalgia & Soft Tissue Disorders
13 Chapter 12: Dermatology, ENT & Ophthalmology
12.1 Common Dermatoses & Dermatological Emergencies 12.2 ENT Presentations: Infections, Epistaxis, Vertigo, Hearing Loss & Head and Neck Lumps 12.3 The Acute Red Eye: Glaucoma, Uveitis & Keratitis 12.4 Sudden & Gradual Vision Loss, Retinal Disorders & the Visual Pathway 12.5 Skin Infections, Infestations, Childhood Rashes & Skin Cancer
14 Chapter 13: Haematology, Oncology & Palliative Care
13.1 Anaemias & Blood Transfusion Medicine 13.2 Haematological Malignancies: Leukaemias, Lymphomas & Myeloma 13.3 Haemostasis, Coagulation Disorders & Anticoagulant Reversal 13.4 Oncological Emergencies & Palliative Symptom Management 13.5 Breast Disease, Cancer Screening & Suspected Cancer Referral
15 Chapter 14: Perioperative Care, Safe Prescribing & Clinical Pharmacology
14.1 Preoperative Assessment & Perioperative Medication Management 14.2 Postoperative Complications & Fluid Therapy 14.3 High-Risk Medications & Therapeutic Drug Monitoring 14.4 Safe Prescribing Principles & Antimicrobial Stewardship
16 Chapter 15: Medical Ethics, Law & UK Clinical Practice
15.1 GMC Good Medical Practice, Professionalism, Teamwork & Quality Improvement 15.2 Consent, Capacity & the Mental Capacity Act 2005 15.3 Confidentiality, Statutory Reporting & DVLA Regulations 15.4 End-of-Life Decisions, DNACPR, Organ Donation, Adult Safeguarding & Domestic Abuse
17 Chapter 16: Infectious Diseases, Travel Medicine & Infection Prevention
16.1 Tuberculosis, HIV, Hepatitis B & C and Needlestick Injuries 16.2 Fever in the Returning Traveller, Zoonoses, Notifiable Diseases & Infection Prevention
18 Chapter 17: Older Adults, Population Health, Genetics & Clinical Imaging
17.1 Frailty, Falls, Polypharmacy, Continence & Pressure Ulcers 17.2 Medical Statistics, Diagnostic Tests & Critical Appraisal 17.3 Public Health, Screening Principles, Health Inequalities & Health Promotion 17.4 Genetics, Genomics & Pharmacogenomics 17.5 Clinical Imaging: Choosing Tests, Radiation Safety & Interpreting X-rays
5.1 Acute Kidney Injury & KDIGO Staging
Key Takeaways Explain This Topic AI
Acute Kidney Injury (AKI) is diagnosed and staged using KDIGO criteria based on acute rises in serum creatinine (≥26.5 µmol/L within 48h or ≥1.5-fold increase within 7 days) and/or sustained reductions in hourly urine output (<0.5 mL/kg/h for ≥6h).
Aetiology is classified into pre-renal (hypoperfusion: volume depletion, sepsis, heart failure; urine Na <20 mmol/L, FeNa <1%), intrinsic renal (ATN, AIN, glomerulonephritis, rhabdomyolysis; urine Na >40 mmol/L, FeNa >2%), and post-renal (urinary obstruction; requires urgent renal ultrasound within 24h).
Initial management centers on rapid cessation of nephrotoxic medications using the DAMN mnemonic (Diuretics, ACEi/ARBs, Metformin, NSAIDs), cautious balanced crystalloid fluid resuscitation for hypovolaemia, and urinary catheterisation for retention or hourly monitoring.
Emergency indications for Renal Replacement Therapy (RRT / dialysis) follow the AEIOU mnemonic: refractory Acidosis (pH <7.15), refractory Electrolyte disturbances (hyperkalaemia >6.5 mmol/L), toxic Ingestions (salicylates, toxic alcohols, lithium), fluid Overload (pulmonary oedema), and severe Uraemic complications (pericarditis, encephalopathy).
Last updated: October 2026
Acute Kidney Injury & KDIGO Staging
Acute Kidney Injury (AKI) represents an abrupt, potentially reversible decline in renal excretory function occurring over hours to days. It leads to the rapid retention of nitrogenous waste products (urea and creatinine), loss of electrolyte and acid-base homeostasis, and dysregulation of intravascular fluid volume. In the National Health Service (NHS), AKI complicates approximately 15–20% of all emergency hospital admissions and is associated with substantial in-hospital morbidity and mortality.
1. Diagnostic Definition & KDIGO Staging Criteria
According to the internationally endorsed Kidney Disease: Improving Global Outcomes (KDIGO) consensus guidelines (adopted by UK NICE Guideline NG148), AKI is diagnosed if any one of the following criteria is fulfilled:
A rise in serum creatinine by ≥ 26.5 µmol/L within 48 hours , OR
A rise in serum creatinine to ≥ 1.5 times baseline , known or presumed to have occurred within the prior 7 days , OR
A documented urine output of < 0.5 mL/kg/hour for at least 6 consecutive hours .
Staging Severity
Once diagnosed, AKI is stratified into three clinical stages according to the magnitude of serum creatinine elevation or the duration and severity of oliguria. When creatinine and urine output yield discordant stages, the higher (more severe) stage is always assigned .
KDIGO Stage Serum Creatinine Criteria Urine Output Criteria
Stage 1 Creatinine 1.5–1.9 times baseline OR an absolute increase of ≥ 26.5 µmol/L within 48 hours < 0.5 mL/kg/hour for 6–12 hours
Stage 2 Creatinine 2.0–2.9 times baseline < 0.5 mL/kg/hour for ≥ 12 hours
Stage 3 Creatinine ≥ 3.0 times baseline OR increase to ≥ 354 µmol/L OR initiation of Renal Replacement Therapy (RRT) < 0.3 mL/kg/hour for ≥ 24 hours OR anuria for ≥ 12 hours
Note
Determining Baseline Creatinine: NHS laboratories in England run the national NHS England AKI detection algorithm on every creatinine result: the reference value is the lowest creatinine in the previous 0–7 days , or, if there is none, the median of results from 8–365 days earlier. A ratio of 1.5 or more generates an AKI warning stage. If no previous result exists, compare with repeat results over the next days (KDIGO also suggests estimating a baseline from an assumed eGFR of 75 mL/min/1.73m²).
2. Aetiological Classification & Diagnostic Differentiation
AKI is mechanistically divided into three anatomical categories: pre-renal , intrinsic renal , and post-renal .
A. Pre-Renal Azotaemia (Renal Hypoperfusion)
Pre-renal AKI accounts for 60–70% of community-acquired cases. It is caused by reduced effective renal arterial perfusion without structural parenchymal damage. If hypoperfusion is rapidly reversed, glomerular filtration rate (GFR) normalises promptly.
Absolute Hypovolaemia: Haemorrhage, gastrointestinal fluid loss (severe vomiting, choleraic diarrhoea), excessive diuresis, burns, severe dehydration.
Relative Hypovolaemia / Vasodilation: Sepsis, anaphylaxis, neurogenic shock, liver cirrhosis with splanchnic arterial vasodilation.
Cardiogenic Pump Failure: Severe acute decompensated heart failure, cardiogenic shock, massive acute myocardial infarction.
Renal Haemodynamic Impairment: Bilateral renal artery stenosis (or unilateral stenosis in a solitary kidney); concurrent administration of ACE inhibitors or Angiotensin Receptor Blockers (which block angiotensin II-mediated efferent arteriolar vasoconstriction) combined with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs, which block prostaglandin-mediated afferent arteriolar vasodilation).
B. Intrinsic Renal AKI (Structural Parenchymal Injury)
Intrinsic AKI involves acute structural damage to the glomeruli, tubules, interstitium, or renal microvasculature:
Acute Tubular Necrosis (ATN): The most common cause of intrinsic AKI in hospitalised patients. Occurs secondary to prolonged, uncorrected renal ischaemia (severe shock, prolonged pre-renal state) or direct nephrotoxic exposure (exogenous toxins: aminoglycosides such as gentamicin, iodinated radiocontrast agents, amphotericin B, cisplatin; endogenous toxins: myoglobin in rhabdomyolysis, hemoglobin in massive intravascular haemolysis, light chains in multiple myeloma).
Acute Interstitial Nephritis (AIN): An immunologically mediated hypersensitivity reaction affecting the renal interstitium. Over 75% of cases are drug-induced, classically triggered by antibiotics (penicillins, cephalosporins, ciprofloxacin, rifampicin), Proton Pump Inhibitors (omeprazole, lansoprazole), NSAIDs, or allopurinol. Autoimmune causes include sarcoidosis, Sjögren's syndrome, and systemic lupus erythematosus (SLE). The classic clinical triad of fever, maculopapular rash, and peripheral eosinophilia is present in only 10–15% of patients (arthralgia may also occur), but urinalysis characteristically demonstrates sterile pyuria, white blood cell casts, and urinary eosinophils .
Acute Glomerulonephritis: Post-streptococcal GN, IgA nephropathy, ANCA-associated vasculitis (granulomatosis with polyangiitis), anti-GBM disease. Characterised by dysmorphic red cells, red cell casts, proteinuria, and active urinary sediment.
Rhabdomyolysis: Massive skeletal muscle necrosis releasing toxic myoglobin into the circulation. Classic causes include trauma, crush injuries, prolonged immobility ("long lie" after a fall in elderly individuals), grand mal seizures, severe exertion, hypothermia, and statin-fibrate interactions. Urinalysis demonstrates a strongly positive dipstick for blood in the complete absence of red blood cells on microscopy (because the reagent strip orthotolidine reaction detects the heme moiety of myoglobin). Serum creatine kinase (CK) is markedly elevated (typically > 10,000 U/L, often > 50,000 U/L). Associated electrolyte disturbances include hyperkalaemia, hyperphosphataemia, hyperuricaemia, and early hypocalcaemia (due to calcium precipitation in necrotic myocytes).
C. Post-Renal AKI (Obstructive Uropathy)
Occurs when acute mechanical obstruction to urinary outflow elevates retrograde hydrostatic pressures within Bowman's space, opposing glomerular filtration:
Bladder Outflow Obstruction: Benign Prostatic Hyperplasia (BPH), prostate adenocarcinoma, blocked urethral catheter, neurogenic bladder, urethral strictures.
Ureteric Obstruction: Bilateral ureteric calculi (or unilateral calculus in a single functional kidney), retroperitoneal fibrosis, retroperitoneal lymphadenopathy, pelvic malignancies (cervical, colorectal, or ovarian carcinoma).
Diagnostic Investigation: Urgent renal tract ultrasound must be performed within 24 hours of presentation (or within 6 hours in suspected pyonephrosis, sepsis, or solitary kidney) to identify pelvicalyceal dilatation (hydronephrosis and hydroureter).
3. Pre-Renal Azotaemia vs. Acute Tubular Necrosis (ATN)
Distinguishing pre-renal hypoperfusion from established ATN is critical because pre-renal failure responds rapidly to fluid resuscitation, whereas established ATN carries a damaged tubular epithelium that cannot concentrate urine or reabsorb sodium, placing the patient at high risk of fluid overload if excessive fluids are given.
Diagnostic Parameter Pre-Renal Azotaemia Acute Tubular Necrosis (ATN)
Pathophysiological State Intact tubular function; avid sodium & water reabsorption Damaged, necrotic tubular epithelium; impaired reabsorption
- Urinary Sodium (Na) < 20 mmol/L (avid conservation) > 40 mmol/L (tubular salt wasting)
- Fractional Excretion of Sodium (FeNa) < 1% > 2%
- Fractional Excretion of Urea (FeUrea) < 35% (useful if patient takes diuretics) > 50%
- Urine Osmolality > 500 mOsm/kg (concentrated urine) < 350 mOsm/kg (isosthenuric; matches plasma)
- Urine : Plasma Urea Ratio > 10 : 1 < 4 : 1
- Urine : Plasma Creatinine Ratio > 40 : 1 < 20 : 1
- Urinary Microscopy Normal OR hyaline casts Muddy brown granular casts , tubular epithelial cell casts
Response to IV Fluid Challenge Rapid urine output rise & creatinine clearance Minimal or no immediate biochemical improvement
FeNa ( % ) = Urinary Sodium × Serum Creatinine Serum Sodium × Urinary Creatinine × 100 \text{FeNa} (\%) = \frac{\text{Urinary Sodium} \times \text{Serum Creatinine}}{\text{Serum Sodium} \times \text{Urinary Creatinine}} \times 100 FeNa ( % ) = Serum Sodium × Urinary Creatinine Urinary Sodium × Serum Creatinine × 100
4. Acute Clinical Management Protocol
Management of AKI follows a structured, evidence-based algorithm:
Step 1: Medication Review & Cessation of Nephrotoxins (DAMN Mnemonic)
Immediate discontinuation of all potentially nephrotoxic or renally cleared agents is mandatory. Remember the DAMN mnemonic:
D – Diuretics: Furosemide, bumetanide, indapamide, spironolactone (withhold immediately unless pulmonary oedema is present).
A – ACE inhibitors / ARBs: Ramipril, lisinopril, losartan, candesartan (withhold; their efferent arteriolar vasodilation lowers glomerular filtration pressure, which worsens GFR when renal perfusion is already reduced).
M – Metformin: Withhold immediately! Metformin is cleared by the kidneys; accumulation during AKI induces life-threatening Metformin-Associated Lactic Acidosis (MALA) .
N – NSAIDs: Ibuprofen, naproxen, diclofenac, meloxicam (stop immediately; inhibits vasodilatory prostaglandins at afferent arterioles).
Additional agents to stop or dose-adjust: Aminoglycosides (gentamicin), vancomycin, amphotericin, iodinated contrast agents, and direct oral anticoagulants (DOACs).
Step 2: Haemodynamic Assessment & Fluid Resuscitation
Hypovolaemic AKI: Administer 500 mL boluses of intravenous balanced crystalloid (e.g. Plasma-Lyte 148 or Hartmann's solution) over 15 minutes, followed by clinical reassessment (pulse, blood pressure, capillary refill time, JVP, chest auscultation). Avoid large volumes of 0.9% normal saline, which induce hyperchloraemic metabolic acidosis and renal vasoconstriction.
Euvolaemic or Hypervolaemic AKI: Fluid boluses are harmful. Restrict maintenance fluid to insensible losses (30–50 mL/h) plus measured urinary output.
Step 3: Urgent Catheterisation & Bladder Decompression
Insert a Foley urinary catheter if urinary retention is suspected, if the patient is haemodynamically unstable, or to enable accurate hourly urine output monitoring in KDIGO Stage 2 or 3 AKI.
5. Emergency Indications for Renal Replacement Therapy: The AEIOU Mnemonic
When conservative medical management fails, urgent nephrology referral for Renal Replacement Therapy (RRT / Haemodialysis) is lifesaving. The emergency indications are memorised using the AEIOU mnemonic:
A – Acidosis (Metabolic): Severe refractory metabolic acidosis with arterial pH < 7.15 or serum bicarbonate < 10 mmol/L, unresponsive to medical therapy.
E – Electrolytes (Hyperkalaemia): Refractory hyperkalaemia with serum potassium > 6.5 mmol/L or rapidly rising levels associated with toxic ECG changes, refractory to insulin-dextrose and calcium gluconate.
I – Ingestions / Toxins: Poisoning with dialysable toxins (mnemonic SLIME : Salicylates, Lithium, Isopropanol, Methanol, Ethylene glycol).
O – Overload (Fluid): Intractable, diuretic-resistant acute pulmonary oedema causing respiratory failure in an oliguric or anuric patient.
U – Uraemia (Complications): Life-threatening end-organ uraemic manifestations: uraemic pericarditis (pericardial friction rub, risk of haemorrhagic tamponade), uraemic encephalopathy (confusion, asterixis, myoclonus, seizures, coma), or uraemic bleeding diathesis secondary to platelet dysfunction.